Intermittent supply constraints due to manufacturing delays from Mylan's manufacturing partner, Meridian Medical Technologies, have resulted in varying supply levels.
The supplemental New Drug Application (sNDA) for the 0.1mg strength was granted Priority Review by the Food and Drug Administration (FDA).
Inpatient and observation unit admissions for pediatric anaphylaxis decreased by more than half following implementation of a revised clinical care pathway.
In this case, a 55-year-old woman developed wheezing, dyspnea, and sudden loss of consciousness during her apitherapy session in which she received live bee stings to improve muscular contractures and stress.
The study enrolled 34 adolescents aged 12 to 17 years old who had no familiarity with an epinephrine device (naive) and did not receive training during the study.
With regard to adverse events, 12.4% of AR101-treated patients discontinued treatment due to treatment-related side effects; these included gastrointestinal adverse events (6.7%) and systemic allergic hypersensitivity reactions (2.7%).
Auvi-Q 0.1mg is the first epinephrine auto-injector specifically designed for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and small children weighing 16.5 to 33 pounds.
Most products were accurate to their stated label, however most products did contain at least 1 unspecified antigen, for instance, "brand of nut-free cookies contained gluten, whereas a gluten-free brand contained a peanut allergen," the authors write.
Results found that 4 children initially treated with PPOIT and 6 treated with placebo had allergic reactions to peanut intake, none experience prophylaxis.
In March and May 2017, two patients given intravenous (IV) infusions of curcumin emulsion compounded with polyethylene glycol (PEG) 40 castor oil reported having immediate hypersensitivity reactions.
The company has indicated that if the new auto-injector is approved they expect it to be available for patients in the first half of 2018.
The researchers found that based on very low certainty in the body of evidence across examined studies, vitamin D supplementation may not reduce the risk of developing allergic diseases.
Symjepi should only be injected into the anterolateral aspect of the thigh; injection into other areas such as the buttocks or the hands and feet may result in adverse effects and may also not provide effective treatment of anaphylaxis.
States in the Midwest and South appear to have the highest prevalence of both alpha-gal allergy and rickettsial diseases transmitted by the Lone Star tick or Amblyomma americanum.
The recall affects both the EpiPen Auto-Injector 0.15mg and 0.3mg strengths and the product was distributed by Mylan Specialty between December 2015 and July 2016.
The patient, a 33-year old woman with a history of drug hypersensitivity to NSAIDs and aspirin, presented for management of her chronic UC with mesalamine.
This clinical report from the American Academy of Pediatrics is an update on their 2007 clinical report.
Findings from a study published in the Annals of Allergy, Asthma & Immunology suggest the ongoing difficulty in diagnosing anaphylaxis as evident by the low prescribing rates of epinephrine auto-injector in cases of anaphylaxis.
Initial trial results have shown that a wearable patch, which delivers small amounts of peanut protein, can protect children and young adults with peanut allergies from the effects of accidental ingestion or exposure.